한국 뇌졸중 진료지침에서 심방세동 환자의 뇌졸중 일차예방에 관한 내용의 부분 개정
Focused Update on Primary Stroke Prevention in Patients with Atrial Fibrillation in Korean Clinical Practice Guidelines for Stroke
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Pivotal clinical trials testing the efficacy of new antithrombotics for the prevention of stroke and systemic embolism in patients with atrial fibrillation have been published since the release of the first edition of Korean clinical practice guidelines for primary stroke prevention. From July 2007 to August 2012, 5 clinical studies and update of guidelines in Europe and North America were identified through systematic search. In patients with atrial fibrillation who were unsuitable for warfarin, the combination of clopidogrel and aspirin reduced the risk of stroke at the cost of increased major bleedings as compared to aspirin. In patients with nonvalvular atrial fibrillation and risk factors for stroke, new oral anticoagulants, dabigatran, rivaroxaban and apixaban,were as effective as or more effective than warfarin in preventing stroke or systemic embolism. The risks of major bleeding with novel anticoagulants were similar to or lower than that of warfarin. Particularly, the risk of intracranial bleeding was significantly lower with novel anticoagulants than with warfarin. In this report, we summarized the new evidences and updated our recommendations for primary stroke prevention in patients with atrial fibrillation.
Abstract
Pivotal clinical trials testing the efficacy of new antithrombotics for the prevention of stroke and systemic embolism in patients with atrial fibrillation have been published since the release of the first edition of Korean clinical practice guidelines for primary stroke prevention. From July 2007 to August 2012, 5 clinical studies and update of guidelines in Europe and North America were identified through systematic search. In patients with atrial fibrillation who were unsuitable for warfarin, the combination of clopidogrel and aspirin reduced the risk of stroke at the cost of increased major bleedings as compared to aspirin. In patients with nonvalvular atrial fibrillation and risk factors for stroke, new oral anticoagulants, dabigatran, rivaroxaban and apixaban,were as effective as or more effective than warfarin in preventing stroke or systemic embolism. The risks of major bleeding with novel anticoagulants were similar to or lower than that of warfarin. Particularly, the risk of intracranial bleeding was significantly lower with novel anticoagulants than with warfarin. In this report, we summarized the new evidences and updated our recommendations for primary stroke prevention in patients with atrial fibrillation.
참고문헌 (15)
- The writing group of clinical practice guideline for stroke, "Clinical Practice Guideline for Stroke" (2009), Clinical Research Center for Stroke
- Connolly SJ, "Effect of clopidogrel added to aspirin in patients with atrial fibrillation", N Engl J Med, 360, pp.2066~2078 (2009)
- Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
- Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
- Connolly SJ, "Apixaban in patients with atrial fibrillation", N Engl J Med, 364, pp.806~817 (2011)
- 정명호, "Apixaban versus warfarin in patients with atrial fibrillation.", NEW ENGLAND JOURNAL OF MEDICINE, 365(11), pp.981~992, MASSACHUSETTS MEDICAL SOC
- Camm AJ, "Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)", Eur Heart J, 31, pp.2369~2429 (2010)
- Camm AJ, "2012 focused update of the ESC Guidelines for the management of atrial fibrillation", Eur Heart J, 33, pp.2719~2747 (2012)
- Wann LS, "2011 ACCF", AHA, Circulation, pp.2011, 123[DOI]
- Fuster V, "2011 ACCF", AHA, AHA, pp.ESC 2006 guidelines for the management of patients with atrial fibrillation, Circulation[DOI]
- Goldstein LB, "Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2011, pp.42, 517~584
- Furie KL, "Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation", Stroke (2012)[DOI]
- Olsen TS, "European Stroke Initiative recommendations for stroke management-update 2003", Cerebrovasc Dis, 16, pp.311~337 (2003)
- Goldstein LB, "Primary prevention of ischemic stroke: a guideline from the American Heart Association", American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline, 2006, pp.37, 1583~1633
- Wann LS, "2011 ACCF", AHA, Circulation, pp.2011, 123[DOI]